-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Recent popular reports from Yimaike ★Pharmaceutical financing ViaCyte raised US$45 million to promote stem cell-derived therapies for type 1 diabetes ★Xu Congcong, head of the microbial mRNA platform research: Nucleic acid drugs are the third milestone in the development of drugs, and we look forward to the combination of different technical routes Strategies Click on the picture and register now.
June 12, 2021/eMedClub News/--The 26th European Hematology Association (EHA) Annual Conference will hold an online conference as scheduled (June 9-17)
.
As the largest international conference in the field of hematology in Europe, it attracts tens of thousands of professionals from more than 100 countries around the world every year, bringing together the world's most cutting-edge clinical research results, and the research results after rigorous screening and selection Debut at the conference
.
The “Innovative CD 19/CD 20 Dual STAR-T Cells for Treatment of Refractory/Relapsed (R/R) Acute B Lymphocytic Leukemia (R/R B-ALL)” jointly launched by Huaxia Yingtai and Lu Daopei Hospital is honored to be one of the few Many were selected as one of the researches of the EHA conference special report
.
Synthetic TCR and Antigen Receptor (STAR) is an innovative chimeric antigen receptor structure jointly developed by Huaxia Yingtai and Tsinghua University.
It is mainly based on T cell receptors.
The framework is functionally modified, and its variable region is replaced with a new antigen receptor structure formed by one or more single-chain antibody (scFV) fragments
.
The basic research results of this structure have been published in "Science Translational Medicine" this year
.
The data reported at the EHA conference this time are the results of early clinical studies of STAR-T products targeting CD19 and CD20 dual targets in relapsed/refractory B-ALL
.
The study was carried out by Hebei Yanda Ludaopei Hospital.
A total of 10 CD19+ and/or CD20+ R/R B-ALL patients were enrolled.
The median age of the enrolled subjects was 23 years old, and the tumor burden ranged from 0.
5% to 53.
%, 9 subjects successfully received CD19/CD20 Dual STAR-T cell infusion and completed follow-up
.
In terms of clinical efficacy, 8 subjects (8/9, 88.
9%) quickly achieved minimal residual disease (MRD) negative complete remission (CR) on Day 14 after cell infusion, and the efficacy was evaluated on Day 28 The results showed that 8/9 is still a complete remission (CR)
.
Among them, 6 (6/8) subjects were bridged with allogeneic hematopoietic stem cell transplantation (HSCT), and the disease remission state can be observed for more than 380 days at the longest
.
Among the two subjects who did not bridge allogeneic hematopoietic stem cell transplantation, one subject became MRD-positive on Day 30 after receiving low-dose cell infusion, and died of recurrent infection (prior-HSCT) on Day D45
.
However, after receiving a high-dose cell infusion, the other subject had a recurrence-free survival (RFS) time of 218 days
.
In terms of safety, no severe cytokine release syndrome (CRS) of grade 3 or above was seen.
Seven subjects developed grade I CRS, and one subject developed grade III immune cell-related neurotoxicity (ICANS)
.
The results of this study suggest that CD19/CD20 Dual STAR-T cells can present good safety and clinical efficacy in R/R B-ALL subjects, and the long-term clinical efficacy is worthy of expanded clinical research
.
Since its establishment in 2018, Huaxia Yingtai has been focusing on the development and commercialization of innovative T-cell immunotherapy products.
It has independently innovative STAR-T and TCR-T technology platforms, and has established a stable process development and quality control industry.
On this basis, the development of more than 10 mature varieties for hematological tumors and solid tumors has been completed, and a number of positive clinical safety and effectiveness data have been obtained
.
The clinical research data of the dual-target CD19/20 STAR-T product appeared on EHA and made a special report at the conference, which represents the recognition of our technology platform and innovation capabilities by international professional institutions, and we look forward to more and better cell therapy products.
Advance to the clinic to benefit more patients
.
June 12, 2021/eMedClub News/--The 26th European Hematology Association (EHA) Annual Conference will hold an online conference as scheduled (June 9-17)
.
As the largest international conference in the field of hematology in Europe, it attracts tens of thousands of professionals from more than 100 countries around the world every year, bringing together the world's most cutting-edge clinical research results, and the research results after rigorous screening and selection Debut at the conference
.
The “Innovative CD 19/CD 20 Dual STAR-T Cells for Treatment of Refractory/Relapsed (R/R) Acute B Lymphocytic Leukemia (R/R B-ALL)” jointly launched by Huaxia Yingtai and Lu Daopei Hospital is honored to be one of the few Many were selected as one of the researches of the EHA conference special report
.
Synthetic TCR and Antigen Receptor (STAR) is an innovative chimeric antigen receptor structure jointly developed by Huaxia Yingtai and Tsinghua University.
It is mainly based on T cell receptors.
The framework is functionally modified, and its variable region is replaced with a new antigen receptor structure formed by one or more single-chain antibody (scFV) fragments
.
The basic research results of this structure have been published in "Science Translational Medicine" this year
.
The data reported at the EHA conference this time are the results of early clinical studies of STAR-T products targeting CD19 and CD20 dual targets in relapsed/refractory B-ALL
.
The study was carried out by Hebei Yanda Ludaopei Hospital.
A total of 10 CD19+ and/or CD20+ R/R B-ALL patients were enrolled.
The median age of the enrolled subjects was 23 years old, and the tumor burden ranged from 0.
5% to 53.
%, 9 subjects successfully received CD19/CD20 Dual STAR-T cell infusion and completed follow-up
.
In terms of clinical efficacy, 8 subjects (8/9, 88.
9%) quickly achieved minimal residual disease (MRD) negative complete remission (CR) on Day 14 after cell infusion, and the efficacy was evaluated on Day 28 The results showed that 8/9 is still a complete remission (CR)
.
Among them, 6 (6/8) subjects were bridged with allogeneic hematopoietic stem cell transplantation (HSCT), and the disease remission state can be observed for more than 380 days at the longest
.
Among the two subjects who did not bridge allogeneic hematopoietic stem cell transplantation, one subject became MRD-positive on Day 30 after receiving low-dose cell infusion, and died of recurrent infection (prior-HSCT) on Day D45
.
However, after receiving a high-dose cell infusion, the other subject had a recurrence-free survival (RFS) time of 218 days
.
In terms of safety, no severe cytokine release syndrome (CRS) of grade 3 or above was seen.
Seven subjects developed grade I CRS, and one subject developed grade III immune cell-related neurotoxicity (ICANS)
.
The results of this study suggest that CD19/CD20 Dual STAR-T cells can present good safety and clinical efficacy in R/R B-ALL subjects, and the long-term clinical efficacy is worthy of expanded clinical research
.
Since its establishment in 2018, Huaxia Yingtai has been focusing on the development and commercialization of innovative T-cell immunotherapy products.
It has independently innovative STAR-T and TCR-T technology platforms, and has established a stable process development and quality control industry.
On this basis, the development of more than 10 mature varieties for hematological tumors and solid tumors has been completed, and a number of positive clinical safety and effectiveness data have been obtained
.
The clinical research data of the dual-target CD19/20 STAR-T product appeared on EHA and made a special report at the conference, which represents the recognition of our technology platform and innovation capabilities by international professional institutions, and we look forward to more and better cell therapy products.
Advance to the clinic to benefit more patients
.
